Protagonist Therapeutics (PTGX)

Executive Summary

Protagonist Therapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary peptide platform to develop novel therapies for hematologic and inflammatory diseases with high unmet need. The lead candidate, rusfertide (PTG-300), a hepcidin mimetic, has completed Phase 2 trials in polycythemia vera (PV) and hereditary hemochromatosis, demonstrating robust efficacy in reducing phlebotomy requirements and normalized hemoglobin levels. With positive Phase 2 data, the company is poised to initiate a pivotal Phase 3 program in PV, representing a major value inflection point. Additionally, Protagonist's oral IL-23 receptor antagonist (PN-235, partnered with Janssen) and an oral peptide (PN-881) are progressing through early development. PN-235 has completed Phase 1 studies in healthy volunteers, and PN-881 is currently in a Phase 1 trial with data expected by mid-2026. The company's focus on oral peptide therapeutics offers a competitive advantage in patient compliance and route of administration. Financially, Protagonist is well-capitalized with a market cap of ~$7.1B, supported by a strong balance sheet and partnership cash flows. Key risks include execution in larger Phase 3 trials and competitive landscape in PV, but rusfertide's differentiated mechanism and compelling clinical data support a favorable risk/reward profile.

Upcoming Catalysts (preview)

• H2 2026Rusfertide (PTG-300) Phase 3 initiation in polycythemia vera80% success
• Q3 2026PN-881 Phase 1 healthy volunteer top-line data60% success
• Q4 2026Janssen partnership update for oral IL-23R antagonist (PN-235) Phase 2 start70% success